There are 61 (9%) feminine urologist enrolled at Sociedad Colombiana de Urología. 41 (40%) of urology residentes in Colombia are ladies. The purpose of this examine is to exhibit the work tendencies of feminine urologist, feminine residents and affected person’s preferences relating to the gender of their urologist. MATERIALS AND METHODS: Descriptive observational sectional examine with nameless surveys carried out to working towards feminine urologists, feminine residents, and sufferers.
The questions evaluated the demographic traits of the surveyed people; the questions for feminine urologists evaluated their work tendencies; for the residents we evaluated their plans as urologists; and the sufferers have been requested about their preferences to be evaluated in medical session and to have a surgical procedure carried out by both a male or feminine urologist. RESULTS: The survey was answered by 53 feminine urologists.
The common age was 37 years, the bulk (54%) labored in Bogotá. 34% have subspecialized, the bulk in andrology (16%) endourology (16%) and pediatric urology (16%). Most of them (73.6%) carry out surgical procedure between 5-20 hours weekly, and essentially the most carried out surgical procedure was varicocelectomy. 34% referred to have been harassed of their work surroundings based mostly on their gender.Thirty-six feminine residents answered the survey. Th eaverage age was 28 years.
The common variety of tutorial publications was 3. 80% want to obtain a sub-specialization, of which 24% would do it in endourology. 41% referred to have been harassed. 188 sufferers answered the survey, 96 males and 87 ladies; 44.1% most well-liked to be attended in medical session by a feminine urologist, and 49.2% most well-liked to be operated by a male urologist. CONCLUSIONS: The variety of feminine urologists has exponentially elevated, simply as the share of feminine residents. Feminine residents want to subspecialize in various areas. Sufferers desire to be attended by a feminine urologist in medical session however desire to have surgical procedure carried out by a male urologist.
Microbiome research in urology– the place will we stand and the place can we attain?
The position of microbiome milieu within the urinary tract, their interaction in various urological circumstances and their therapeutic implications should not utterly understood. The microbiome has contributed in the direction of urinary tract infections, urolithiasis and urological cancers. The potential of manipulating microbiome for prognosis and remedy is evolving. Probiotics would possibly assist in overcoming the issues of recurrent an infection and antibiotic resistance.
Novel purposes like stents and catheters coated with non-pathogenic organisms are being developed. Analysis within the urinary microbiome has progressed from utilizing mouse fashions to the presently out there three- dimensional cultured organoids, thus making it extra possible. As our information relating to the urinary microbiome will increase, justice might be carried out to many sufferers in whom the developments can be utilized for prophylaxis, prognosis, remedy and even in enhancing their high quality of life.
The rising quantity of antibiotic resistance can be a matter of concern and probiotics is perhaps the reply to this upcoming calamity. On this assessment, we’ve mentioned the position of the urinary microbiome in pathogenesis, prognosis and remedy of urological circumstances and contemplated upon its future prospects.

Way of life in urology: Benign illnesses
Modifiable lifestyle-related threat elements are the thing of accelerating consideration, with a view to main and tertiary prevention, to restrict the onset and improvement of illnesses.Additionally within the urological area there may be accumulating proof of the connection between urological illnesses and lifestyle-related threat elements that may affect their incidence and prognosis.
Danger elements resembling diet, bodily exercise, sexual habits, tobacco smoking, or alcohol consumption might be modified to restrict morbidity and scale back the social impression and the burdensome prices related to prognosis and remedy.
This assessment synthesizes the present scientific proof out there on this subject, attempting to fulfill the necessity for a abstract on the relationships between crucial way of life elements and the primary benign urological illnesses, specializing in benign prostatic hyperplasia (BPH), infections urinary tract (UTI), urinary incontinence (UI), stones, erectile dysfunction, and male infertility.
COVID-19 in european urology : Which classes have we realized?
The coronavirus has challenged all medical methods worldwide. Herein each waves of COVID-19 (coronavirus illness 2019) in spring and autumn 2020 differ principally. Whereas Europe was hit by the primary wave roughly unprepared, which was aggravated by the excessive virulence of COVID-19, the second wave is characterised by a a lot larger contagiosity of the virus with very excessive incidences.
However the virus has attenuated, which is mirrored by the considerably decrease incidence-related mortality fee. Nonetheless, the general rising variety of contaminated sufferers represents once more an important problem for the medical administration of the illness. France and Spain are doing higher compared to Germany and Italy this time.
Absolutely the variety of deaths per week is larger than throughout the peak of the primary wave. Nonetheless, urologists in these nations have additionally skilled better restrictions of their actions within the second shutdown than in Germany, the place there may be solely a discount of beds to between 75 and 90%.
Largely all ranges are operated. Of significance for Germany, nevertheless, is the plateau on a excessive degree for a number of weeks most likely because of the decreased efficacy of a lightweight lock-down. This lastly resulted in a complete lock-down in mid-December 2020. Subsequently in Germany some hospitals are additionally reaching their limits with related penalties for the departments of urology going through a 50% discount of beds and working solely degree III and IV indications.
Mouse LIF |
|
300-365P-500ug |
GeminiBio |
500 µg |
Ask for price |
Mouse LIF |
|
300-365P-5ug |
GeminiBio |
5 µg |
Ask for price |
LIF,Mouse |
|
E34M066M |
EnoGene |
5 μg |
EUR 155 |
LIF, mouse |
|
MO16102 |
Neuromics |
100 ug |
EUR 494.1 |
LIF, Mouse |
|
MBS8575391-0005mg |
MyBiosource |
0.005mg |
EUR 245 |
LIF, Mouse |
|
MBS8575391-5x0005mg |
MyBiosource |
5x0.005mg |
EUR 940 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592457-01mg |
MyBiosource |
0.1mg |
EUR 365 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592457-05mg |
MyBiosource |
0.5mg |
EUR 530 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592457-5x05mg |
MyBiosource |
5x0.5mg |
EUR 2140 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592458-01mg |
MyBiosource |
0.1mg |
EUR 365 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592458-05mg |
MyBiosource |
0.5mg |
EUR 530 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592458-5x05mg |
MyBiosource |
5x0.5mg |
EUR 2140 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592459-01mg |
MyBiosource |
0.1mg |
EUR 365 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592459-05mg |
MyBiosource |
0.5mg |
EUR 530 |
Mouse Anti-Human LIF Monoclonal Antibody |
|
MBS592459-5x05mg |
MyBiosource |
5x0.5mg |
EUR 2140 |
Mouse LIF (AF) |
|
300-838P-100ug |
GeminiBio |
100 µg |
Ask for price |
Mouse LIF (AF) |
|
300-838P-1mg |
GeminiBio |
1 mg |
Ask for price |
Mouse LIF (AF) |
|
300-838P-20ug |
GeminiBio |
20 µg |
Ask for price |
Mouse LIF (AF) |
|
300-838P-500ug |
GeminiBio |
500 µg |
Ask for price |
Mouse LIF (AF) |
|
300-838P-5ug |
GeminiBio |
5 µg |
Ask for price |
Mouse LIF siRNA |
|
20-abx922546 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Mouse LIF Protein |
|
E2PD201245 |
EnoGene |
20ug |
EUR 595 |
Mouse LIF Protein |
|
E40MOP1672 |
EnoGene |
20ug |
EUR 495 |
Mouse LIF Protein |
|
E40MOP2026 |
EnoGene |
20ug |
EUR 495 |
Mouse LIF Protein |
|
E40MOP2028 |
EnoGene |
20ug |
EUR 495 |
LIF, Mouse, Monoclonal Antibody, Mouse |
|
MBS555093-01mg |
MyBiosource |
0.1mg |
EUR 745 |
LIF, Mouse, Monoclonal Antibody, Mouse |
|
MBS555093-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3210 |
LIF siRNA (Mouse) |
|
MBS8224619-15nmol |
MyBiosource |
15nmol |
EUR 405 |
LIF siRNA (Mouse) |
|
MBS8224619-30nmol |
MyBiosource |
30nmol |
EUR 565 |
LIF siRNA (Mouse) |
|
MBS8224619-5x30nmol |
MyBiosource |
5x30nmol |
EUR 2450 |
Recombinant Mouse LIF |
|
MBS4159936-001mg |
MyBiosource |
0.01mg |
EUR 230 |
Recombinant Mouse LIF |
|
MBS4159936-01mg |
MyBiosource |
0.1mg |
EUR 560 |
Recombinant Mouse LIF |
|
MBS4159936-1mg |
MyBiosource |
1mg |
EUR 1500 |
Recombinant Mouse LIF |
|
MBS4159936-5x1mg |
MyBiosource |
5x1mg |
EUR 6500 |
Recombinant Mouse LIF |
|
MBS7609292-005mg |
MyBiosource |
0.05mg |
EUR 405 |
Recombinant Mouse LIF |
|
MBS7609292-02mg |
MyBiosource |
0.2mg |
EUR 760 |
Recombinant Mouse LIF |
|
MBS7609292-1mg |
MyBiosource |
1mg |
EUR 2175 |
Recombinant Mouse LIF |
|
MBS7609292-5x1mg |
MyBiosource |
5x1mg |
EUR 8410 |
Recombinant Mouse LIF |
|
P1174-.005 |
ApexBio |
5ug |
EUR 108.8 |
|
Description: Peptides & Proteins|Recombinant Proteins |
Recombinant Mouse LIF |
|
P1174-.1 |
ApexBio |
100ug |
EUR 840.8 |
|
Description: Peptides & Proteins|Recombinant Proteins |
Recombinant Mouse LIF |
|
P1174-.5 |
ApexBio |
500ug |
EUR 1885.6 |
|
Description: Peptides & Proteins|Recombinant Proteins |
Recombinant Mouse LIF |
|
Z200195 |
ABM |
10 µg |
EUR 85 |
|
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation. It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1. The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
Recombinant Mouse LIF |
|
Z200197 |
ABM |
100 µg |
EUR 385 |
|
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation. It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1. The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
Recombinant Mouse LIF |
|
Z200199 |
ABM |
1.0 mg |
EUR 1200 |
|
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation (2). It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1 (2). The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
Recombinant Mouse LIF |
|
Z200485 |
ABM |
100 µg |
EUR 1500 |
|
Description: LIF is a multifunctional secreted glycoprotein that exists in both soluble and matrix-bound forms. It displays biologic activities ranging from the differentiation of myeloid leukemic cells into macrophage lineage to effects on bone metabolism, inflammation, neural development, embryogenesis, and the maintenance of implantation (2). It is now clear that LIF is related in both structure and mechanism of action to the interleukin IL-6 family of cytokines, which also includes IL-11, ciliary neurotrophic factor, oncostatin M, and cardiotrophin 1 (2). The actions of these cytokines are mediated through specific cell-surface receptors that consist of a unique chain and the shared signal transducing subunit gp130. |
LIF Protein, Mouse |
|
UA040061 |
Starter Biotechnology Co Ltd |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 5 µg
- 10 µg
- 50 µg
- 100 µg
- 500 µg
- 1 mg
|
Anti-Mouse LIF Antibody |
|
103-M263 |
ReliaTech |
100 µg |
EUR 399 |
|
Description: Based on its helical structure, LIF (Leukemia Inhibitory Factor) is considered a member of the Interleukin-6 family of cytokines. Functionally, it has been implicated in a many physiological processes including development, hematopoiesis, bone metabolism, and inflammation. Some cell types known to express LIF include activated T cells, monocytes, astrocytes, osteoblasts, keratinocytes, regenerating skeletal muscle, mast cells, and fibroblasts. |
Anti-Mouse LIF Antibody |
|
103-PA05S |
ReliaTech |
100 µg |
EUR 126 |
|
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. |
LIF (mouse), (recombinant) |
|
MBS566073-1mL |
MyBiosource |
1mL |
EUR 1470 |
LIF (mouse), (recombinant) |
|
MBS566073-5x1mL |
MyBiosource |
5x1mL |
EUR 6555 |
LIF, Mouse Recombinant |
|
L4500 |
GenDepot |
1 MIU/mL |
Ask for price |
Mouse LIF ELISA Kit |
|
E28L0650 |
EnoGene |
96T |
EUR 666.67 |
Mouse LIF ELISA Kit |
|
EK5250 |
SAB |
96 tests |
EUR 599 |
|
|
Mouse LIF ELISA Kit |
|
EML0014 |
Abclonal |
96Tests |
EUR 625.2 |
Mouse LIF shRNA Plasmid |
|
20-abx971321 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Lif (NM_008501) Mouse Recombinant Protein |
|
E45M43185M5 |
EnoGene |
20 ug |
EUR 1924.54 |
Lif (NM_008501) Mouse Recombinant Protein |
|
E45M42302E0 |
EnoGene |
20 ug |
EUR 1088.75 |
LIF, Human, Monoclonal Antibody, Mouse |
|
MBS555094-01mg |
MyBiosource |
0.1mg |
EUR 745 |
LIF, Human, Monoclonal Antibody, Mouse |
|
MBS555094-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3210 |
Recombinant Mouse LIF protein |
|
CD00323-5ug |
Jiaxing Korain Biotech Ltd (BT Labs) |
5ug |
EUR 176 |
|
|
|
Description: Leukemia inhibitory factor (LIF) is a member of Interleukin 6 family. This protein is mainly expressed in the trophectoderm of the developing embryo, with its receptor LIFR expressed throughout the inner cell mass. LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes. LIF is used in mouse embryonic stem cell culture, because that removal of LIF pushes stem cells toward differentiation, but they retain their proliferative potential or pluripotency. It is also used in phase II clinical trial, which can assist embryo implantation in women who have failed to become pregnant despite assisted reproductive technologies (ART). Mature mouse LIF shares 78 % a.a. sequence identity with Human LIF. |
Recombinant Mouse LIF protein |
|
IMP-1308 |
Creative BioMart |
10µg |
EUR 360 |
|
|
|
Description: Recombinant Proteins |
Mouse LIF Recombinant Protein |
|
M30-007 |
ReliaTech |
10 µg |
EUR 99.75 |
|
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. Recombinant mouse LIF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 180 amino acids and having a molecular mass of 19.86 kDa. |
Mouse LIF Recombinant Protein |
|
M30-008 |
ReliaTech |
50 µg |
EUR 246.75 |
|
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. Recombinant mouse LIF produced in E. coli is a single, non-glycosylated, polypeptide chain containing 180 amino acids and having a molecular mass of 19.86 kDa. |
Recombinant Mouse LIF Protein |
|
MBS1751002-01mg |
MyBiosource |
0.1mg |
EUR 315 |
Recombinant Mouse LIF Protein |
|
MBS1751002-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1270 |
Recombinant Mouse LIF Protein |
|
MBS8249390-001mg |
MyBiosource |
0.01mg |
EUR 230 |
Recombinant Mouse LIF Protein |
|
MBS8249390-005mg |
MyBiosource |
0.05mg |
EUR 480 |
Recombinant Mouse LIF Protein |
|
MBS8249390-05mg |
MyBiosource |
0.5mg |
EUR 2825 |
Recombinant Mouse LIF Protein |
|
MBS8249390-5x05mg |
MyBiosource |
5x0.5mg |
EUR 12640 |
Recombinant Mouse LIF Protein |
|
PKSM041100-100ug |
Elabscience Biotech |
100ug |
EUR 739 |
|
|
|
Description: Mouse |
Recombinant Mouse LIF Protein |
|
PKSM041100-20ug |
Elabscience Biotech |
20ug |
EUR 249 |
|
|
|
Description: Mouse |
Recombinant Mouse LIF Protein |
|
R01400-1 |
BosterBio |
100ug/vial |
EUR 240 |
|
|
|
Description: SPLPI TPVNA TCAIR HPCHG NLMNQ IKNQL AQLNG SANAL FISYY TAQGE PFPNN VEKLC APNMT DFPSF HGNGT EKTKL VELYR MVAYL SASLT NITRD QKVLN PTAVS LQVKL NATID VMRGL LSNVL CRLCN KYRVG HVDVP PVPDH SDKEA FQRKK LGCQL LGTYK QVISV VVQAF |
Recombinant Mouse LIF Protein |
|
PM0130M2 |
Leading Biology |
20 µg |
Ask for price |
|
Description: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate.LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation. p53 regulated LIF has been shown to facilitate implantation in the mouse model and possibly in humans. It has been suggested that recombinant human LIF might help to improve the implantation rate in women with unexplained infertility. |
LIF Protein, Mouse, Recombinant |
|
E45M52739M0-20-ug |
EnoGene |
20 ug |
EUR 291.15 |
LIF Protein, Mouse, Recombinant |
|
PM52739M0 |
Leading Biology |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
Anti-LIF Antibody, Mouse Monoclonal |
|
MBS8107490-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-LIF Antibody, Mouse Monoclonal |
|
MBS8107490-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
Mouse LIF, C-His Tag |
|
HA210735 |
HUABIO |
100 µg |
Ask for price |
anti- LIF antibody |
|
FNab09804 |
FN Test |
100µg |
EUR 658.5 |
|
|
|
Description: Antibody raised against LIF |
Mouse LIF PicoKine ELISA Kit |
|
MBS178717-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 2755 |
Mouse LIF PicoKine ELISA Kit |
|
MBS178717-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 600 |
Recombinant Mouse LIF, Tag Free |
|
PM2019-.01 |
ApexBio |
10ug |
EUR 208 |
|
Description: Peptides & Proteins|Recombinant Proteins |
Recombinant Mouse LIF, Tag Free |
|
PM2019-.1 |
ApexBio |
10X10ug |
EUR 784 |
|
Description: Peptides & Proteins|Recombinant Proteins |
Lif ORF Vector (Mouse) (pORF) |
|
ORF049145 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Lif ORF Vector (Mouse) (pORF) |
|
ORF049146 |
ABM |
1.0 ug DNA |
EUR 607.2 |
LIF, Mouse Recombinant , 1MIU/ml |
|
L4500-001 |
GenDepot |
1ml |
EUR 235 |
LIF, Mouse Recombinant , 1MIU/ml |
|
L4500-005 |
GenDepot |
5x1ml |
EUR 890 |
LIF ELISA Kit (Mouse) (OKBB00760) |
|
OKBB00760 |
Aviva Systems Biology |
96 Wells |
EUR 606 |
|
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml |
LIF ELISA Kit (Mouse) (OKEH04045) |
|
OKEH04045 |
Aviva Systems Biology |
96 Wells |
EUR 652.8 |
|
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL |
LIF, Mouse Recombinant , 10MIU/ml |
|
L4501-001 |
GenDepot |
1ml |
EUR 1100 |
Purified recombinant Mouse LIF protein |
|
MBS5308803-001mg |
MyBiosource |
0.01mg |
EUR 550 |
Purified recombinant Mouse LIF protein |
|
MBS5308803-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2435 |
Mouse LIF HEK293 Overexpression Lysate |
|
MBS8119752-03mg |
MyBiosource |
0.3mg |
EUR 280 |
Mouse LIF HEK293 Overexpression Lysate |
|
MBS8119752-5x03mg |
MyBiosource |
5x0.3mg |
EUR 1205 |
Mouse LIF HEK293 Overexpression Lysate |
|
MBS8119753-03mg |
MyBiosource |
0.3mg |
EUR 280 |
Mouse LIF HEK293 Overexpression Lysate |
|
MBS8119753-5x03mg |
MyBiosource |
5x0.3mg |
EUR 1205 |
LIFR, Recombinant, Mouse (Leukemia Inhibitory Factor Receptor, LIF Receptor, LIF-R, D-factor/LIF Receptor, CD118) |
|
MBS636029-005mg |
MyBiosource |
0.05mg |
EUR 800 |
LIFR, Recombinant, Mouse (Leukemia Inhibitory Factor Receptor, LIF Receptor, LIF-R, D-factor/LIF Receptor, CD118) |
|
MBS636029-5x005mg |
MyBiosource |
5x0.05mg |
EUR 3455 |
Mouse LIF Recombinant Protein Lyophilized |
|
IMSLIFRLY5UG |
Innovative research |
each |
EUR 317 |
|
|
|
Description: Mouse LIF Recombinant Protein Lyophilized |
Mouse LIF Recombinant Protein Lyophilized |
|
MBS8434242-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Human CellExp? LIF, mouse recombinant |
|
7268-10 |
Biovision |
each |
EUR 444 |
Leukemia Inhibitory Factor (LIF), Mouse |
|
MBS555550-0005mg |
MyBiosource |
0.005mg |
EUR 500 |
Leukemia Inhibitory Factor (LIF), Mouse |
|
MBS555550-001mg |
MyBiosource |
0.01mg |
EUR 670 |
Leukemia Inhibitory Factor (LIF), Mouse |
|
MBS555550-5x001mg |
MyBiosource |
5x0.01mg |
EUR 2855 |
Leukemia Inhibitory Factor (LIF), mouse |
|
PR16102 |
Neuromics |
5 ug |
EUR 310.5 |
Leukemia Inhibitory Factor (LIF), mouse |
|
PR16102-B |
Neuromics |
each |
EUR 436.5 |
Mouse LIF protein, C-His tag |
|
MBS9719051-0005mg |
MyBiosource |
0.005mg |
EUR 115 |
Mouse LIF protein, C-His tag |
|
MBS9719051-002mg |
MyBiosource |
0.02mg |
EUR 165 |
Mouse LIF protein, C-His tag |
|
MBS9719051-01mg |
MyBiosource |
0.1mg |
EUR 295 |
Mouse LIF protein, C-His tag |
|
MBS9719051-1mg |
MyBiosource |
1mg |
EUR 1680 |
Mouse LIF protein, C-His tag |
|
MBS9719051-5x1mg |
MyBiosource |
5x1mg |
EUR 7520 |
Mouse LIF protein, C-His tag |
|
PRP1126-100ug |
Abbkine |
100 μg |
EUR 379 |
|
Description: Mouse LIF protein, C-His tag, expressed in E. coli |
Mouse LIF protein, C-His tag |
|
PRP1126-1mg |
Abbkine |
1 mg |
EUR 2509 |
|
Description: Mouse LIF protein, C-His tag, expressed in E. coli |
Mouse LIF protein, C-His tag |
|
PRP1126-20ug |
Abbkine |
20 μg |
EUR 149 |
|
Description: Mouse LIF protein, C-His tag, expressed in E. coli |
Mouse LIF protein, C-His tag |
|
PRP1126-5ug |
Abbkine |
5 μg |
EUR 59 |
|
Description: Mouse LIF protein, C-His tag, expressed in E. coli |
Mouse LIF ELISA Kit PicoKine® |
|
EK0580 |
BosterBio |
96 wells |
EUR 499 |
|
|
|
Description: Mouse LIF ELISA Kit PicoKine® (96 Tests). Quantitate Mouse Lif in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 10pg/ml. |
Lif (untagged) - Mouse leukemia inhibitory factor (Lif), transcript variant 1, (10ug) |
|
MC208887 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lif (untagged) - Mouse leukemia inhibitory factor (Lif), transcript variant 2, (10ug) |
|
MC208888 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Recombinant Mouse Lif Protein, No Tag |
|
E40MOP2217 |
EnoGene |
20ug |
EUR 495 |
Recombinant Mouse Lif Protein, No Tag |
|
MOP2217 |
KMD Bioscience |
-
Ask for price
-
Ask for price
|
|
Anti-Human LIF Antibody |
|
101-M553 |
ReliaTech |
100 µg |
EUR 399 |
|
Description: Based on its helical structure, LIF (Leukemia Inhibitory Factor) is considered a member of the Interleukin-6 family of cytokines. Functionally, it has been implicated in a many physiological processes including development, hematopoiesis, bone metabolism, and inflammation. Some cell types known to express LIF include activated T cells, monocytes, astrocytes, osteoblasts, keratinocytes, regenerating skeletal muscle, mast cells, and fibroblasts. |
Anti-Human LIF Antibody |
|
102-PA05S |
ReliaTech |
100 µg |
EUR 126 |
|
Description: Leukemia Inhibitory Factor also called LIF is a lymphoid factor that promotes long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation. Leukemia Inhibitory Factor has several functions such as cholinergic neuron differentiation, control of stem cell pluripotency, bone & fat metabolism, mitogenesis of factor dependent cell lines & promotion of megakaryocyte production in vivo. Human and mouse LIF exhibit a 78% identity in its amino acid sequence. Human LIF is as active on human cells as is it is on mouse cells, though mouse LIF is about 1000 fold less active on human cells, than human LIF. |
Recombinant Mouse Lif Protein, low endotoxin |
|
EPLE-19M |
Creative BioMart |
10ug |
EUR 263.2 |
|
Description: Mouse |
Lif (GFP-tagged) - Mouse leukemia inhibitory factor (Lif) transcript variant 1, (10ug) |
|
MG223120 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lif (GFP-tagged) - Mouse leukemia inhibitory factor (Lif) transcript variant 2, (10ug) |
|
MG223901 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lif (Myc-DDK-tagged) - Mouse leukemia inhibitory factor (Lif), transcript variant 1 |
|
MR223120 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lif (Myc-DDK-tagged) - Mouse leukemia inhibitory factor (Lif), transcript variant 2 |
|
MR223901 |
Origene Technologies GmbH |
10 µg |
Ask for price |
However, the administration of urologic sufferers throughout the COVID-19 pandemic is carried out in Europa on a excessive commonplace. Therefor the danger of secondary hurt to our sufferers is anticipated to be reasonably minimal in the long term.